Abstract
This Journal club aims to evaluate the recent evidence about the potential benefits of macrolides as add-on therapy in the treatment of community-acquired pneumonia (CAP), an area where the data remain conflicting. Four studies with diverse methodology (the ACCESS trial, a Greek cohort study, a UK-based cohort study and a recent meta-analysis) have aimed to assess either potential immunomodulatory effects, clinical response or hard end-points like mortality when macrolides are added to the treatment regimen for hospitalised patients with CAP. The ACCESS trial, a randomised controlled trial (RCT), demonstrated improved early clinical response and immunomodulatory effects with clarithromycin, while the Greek cohort study showed reduced 28-day mortality and delayed organ dysfunction with clarithromycin. The cohort study from the UK found no added benefit of macrolides on 30-day mortality or decline in Sequential Organ Failure Assessment score. The recent meta-analysis supported a survival advantage of macrolides, favouring clarithromycin over azithromycin. However, study limitations like heterogeneity, confounding risks and the lack of head-to-head comparisons of individual macrolides remain of concern. Macrolide treatment decisions may benefit from individualised risk assessment; however, future research should focus on identifying subgroups who might benefit from macrolides and comparative analyses of macrolide agents through large-scale RCTs.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 250190 |
| Tidsskrift | Breathe |
| Vol/bind | 21 |
| Udgave nummer | 4 |
| Sider (fra-til) | 250190 |
| ISSN | 1810-6838 |
| DOI | |
| Status | Udgivet - okt. 2025 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'The use of macrolides in the treatment of community-acquired pneumonia: risks and benefits'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS